-
Product Insights
Hepatitis D – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis D - Drugs In Development, 2023’, provides an overview of the Hepatitis D pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Complement Factor D – Drugs In Development, 2023
Global Markets Direct’s Complement Factor D provides in depth analysis on Complement Factor D targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement Factor D targeted therapeutics...
-
Product Insights
Vitamin D Deficiency Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitamin D Deficiency Disorders - Drugs In Development, 2023’, provides an overview of the Vitamin D Deficiency Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitamin D Deficiency Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Vascular Endothelial Growth Factor D – Drugs In Development, 2023
Global Markets Direct’s Vascular Endothelial Growth Factor D provides in depth analysis on Vascular Endothelial Growth Factor D targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daplusiran in Hepatitis D
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Daplusiran in Hepatitis D Drug Details: JNJ-3989 (ARO-HBV) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hepalatide in Hepatitis D
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Hepalatide in Hepatitis D Drug Details: Synthetic Peptide (L-47) is under development for the treatment...
-
Product Insights
NKG2 D Type II Integral Membrane Protein – Drugs In Development, 2023
Global Markets Direct’s NKG2 D Type II Integral Membrane Protein provides in depth analysis on NKG2 D Type II Integral Membrane Protein targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HH-006 in Hepatitis D
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HH-006 in Hepatitis D Drug Details: HH-006 is under development for the treatment of Hepatitis...
-
Product Insights
FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase – Drugs In Development, 2023
Global Markets Direct’s FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase provides in depth analysis on FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase targeted therapeutics...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2b LA in Hepatitis D
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2b LA in Hepatitis D Drug Details: Ropeginterferon alpha-2b (Besremi) is a long acting...